Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of
SURPASS
‐3
MRI
Kenneth Cusi, Amalia Gastaldelli, Laura Fernández Landó, Palash Sharma, Amelia Torcello‐Gómez, Ángel Rodríguez ABSTRACT
The patatin‐like phospholipase 3 (PNPLA3) I148M genetic variant is highly associated with steatotic liver disease. In the SURPASS‐3 MRI substudy, tirzepatide significantly reduced liver fat content (LFC) versus insulin degludec in insulin‐naïve patients with type 2 diabetes with metabolic dysfunction‐associated steatotic liver disease. The influence of PNPLA3 I148M allele on changes in LFC in response to tirzepatide is unknown. This post hoc analysis evaluated changes in MRI‐assessed LFC and cardiometabolic parameters by presence (genotypes GG and CG) or absence (genotype CC) of the PNPLA3 I148M allele after 52‐week treatment. Tirzepatide‐treated participants experienced significant reductions in LFC, weight, HbA 1c , and overall greater improvement in lipids and liver enzymes regardless of the presence of PNPLA3 I148M allele. Findings were consistent across genotype subgroups. In this exploratory analysis, the presence of PNPLA3 I148M allele did not seem to affect tirzepatide‐induced improvement in LFC and several cardiometabolic parameters in patients with type 2 diabetes.
Trial Registration: